Nifty
Sensex
:
:
10767.40
36330.65
-73.25 (-0.68%)
-233.23 (-0.64%)

Pharmaceuticals & Drugs

Rating :
51/99  (View)

BSE: 532321 | NSE: CADILAHC

237.90
-3.35 (-1.39%)
19-Sep-2019 | 9:59AM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  242.00
  •  242.45
  •  237.70
  •  241.25
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  160521
  •  381.88
  •  414.80
  •  206.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 24,692.67
  • 14.60
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 31,947.89
  • 1.45%
  • 2.31

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.79%
  • 1.82%
  • 5.95%
  • FII
  • DII
  • Others
  • 3.93%
  • 7.80%
  • 5.71%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.57
  • 8.76
  • 11.98

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.89
  • 11.09
  • 9.31

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.54
  • 9.43
  • 7.42

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.04
  • 26.38
  • 25.06

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.91
  • 6.07
  • 5.09

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.20
  • 17.90
  • 17.38

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Net Sales
3,496.30
2,893.70
20.82%
3,732.80
3,250.20
14.85%
3,577.90
3,259.90
9.75%
2,961.20
3,221.90
-8.09%
Expenses
2,864.30
2,248.70
27.38%
2,932.40
2,379.80
23.22%
2,738.00
2,401.30
14.02%
2,273.40
2,364.80
-3.87%
EBITDA
632.00
645.00
-2.02%
800.40
870.40
-8.04%
839.90
858.60
-2.18%
687.80
857.10
-19.75%
EBIDTM
18.08%
22.29%
21.44%
26.78%
23.47%
26.34%
23.23%
26.60%
Other Income
22.60
101.30
-77.69%
38.40
28.70
33.80%
31.00
25.70
20.62%
30.40
22.50
35.11%
Interest
89.10
35.00
154.57%
77.30
15.40
401.95%
45.50
13.40
239.55%
35.70
40.50
-11.85%
Depreciation
171.60
141.80
21.02%
155.60
144.00
8.06%
153.70
146.90
4.63%
147.50
126.30
16.79%
PBT
393.90
569.50
-30.83%
605.90
739.70
-18.09%
671.70
724.00
-7.22%
535.00
712.80
-24.94%
Tax
79.10
120.30
-34.25%
126.70
144.20
-12.14%
158.60
178.60
-11.20%
124.70
212.30
-41.26%
PAT
314.80
449.20
-29.92%
479.20
595.50
-19.53%
513.10
545.40
-5.92%
410.30
500.50
-18.02%
PATM
9.00%
15.52%
12.84%
18.32%
14.34%
16.73%
13.86%
15.53%
EPS
2.96
4.50
-34.22%
4.49
5.77
-22.18%
4.99
5.31
-6.03%
4.08
4.92
-17.07%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
13,768.20
13,165.60
11,904.90
9,376.50
9,426.80
8,651.30
7,224.00
6,357.70
5,263.30
4,630.60
3,686.80
Net Sales Growth
9.05%
10.59%
26.97%
-0.53%
8.96%
19.76%
13.63%
20.79%
13.66%
25.60%
 
Cost Of Goods Sold
4,989.30
4,141.30
3,656.90
3,065.00
2,673.20
2,814.10
2,412.60
2,036.80
1,464.10
1,286.20
1,011.20
Gross Profit
8,778.90
9,024.30
8,248.00
6,311.50
6,753.60
5,837.20
4,811.40
4,320.90
3,799.20
3,344.40
2,675.60
GP Margin
63.76%
68.54%
69.28%
67.31%
71.64%
67.47%
66.60%
67.96%
72.18%
72.22%
72.57%
Total Expenditure
10,808.10
10,197.60
9,076.30
7,475.00
7,097.30
6,897.40
6,031.20
5,234.00
4,181.50
3,614.10
2,878.20
Power & Fuel Cost
-
247.20
226.30
174.50
168.80
145.40
129.70
124.40
93.40
78.90
66.00
% Of Sales
-
1.88%
1.90%
1.86%
1.79%
1.68%
1.80%
1.96%
1.77%
1.70%
1.79%
Employee Cost
-
2,099.40
1,820.30
1,485.20
1,261.60
1,096.50
974.00
818.40
679.90
584.00
401.10
% Of Sales
-
15.95%
15.29%
15.84%
13.38%
12.67%
13.48%
12.87%
12.92%
12.61%
10.88%
Manufacturing Exp.
-
1,334.70
1,197.50
955.30
1,019.60
1,136.90
936.50
897.30
718.90
553.40
429.10
% Of Sales
-
10.14%
10.06%
10.19%
10.82%
13.14%
12.96%
14.11%
13.66%
11.95%
11.64%
General & Admin Exp.
-
589.10
509.50
466.00
432.70
326.80
365.70
342.20
271.90
234.90
218.50
% Of Sales
-
4.47%
4.28%
4.97%
4.59%
3.78%
5.06%
5.38%
5.17%
5.07%
5.93%
Selling & Distn. Exp.
-
1,035.40
1,014.50
826.40
979.60
960.30
902.40
857.50
767.40
710.70
585.30
% Of Sales
-
7.86%
8.52%
8.81%
10.39%
11.10%
12.49%
13.49%
14.58%
15.35%
15.88%
Miscellaneous Exp.
-
750.50
651.30
502.60
561.80
417.40
310.30
157.40
185.90
166.00
585.30
% Of Sales
-
5.70%
5.47%
5.36%
5.96%
4.82%
4.30%
2.48%
3.53%
3.58%
4.53%
EBITDA
2,960.10
2,968.00
2,828.60
1,901.50
2,329.50
1,753.90
1,192.80
1,123.70
1,081.80
1,016.50
808.60
EBITDA Margin
21.50%
22.54%
23.76%
20.28%
24.71%
20.27%
16.51%
17.67%
20.55%
21.95%
21.93%
Other Income
122.40
206.20
133.00
147.10
116.60
57.20
58.00
38.40
53.00
22.80
15.90
Interest
247.60
193.50
110.80
63.10
52.80
67.90
90.20
168.70
182.70
69.90
82.10
Depreciation
628.40
598.60
538.80
373.30
292.10
287.30
201.20
184.70
157.90
126.90
133.90
PBT
2,206.50
2,382.10
2,312.00
1,612.20
2,101.20
1,455.90
959.40
808.70
794.20
842.50
608.50
Tax
489.10
530.30
564.40
128.90
177.40
259.40
106.00
118.80
113.00
106.40
74.10
Tax Rate
22.17%
22.26%
24.41%
8.00%
8.45%
17.95%
11.25%
14.69%
14.23%
12.63%
12.27%
PAT
1,717.40
1,801.90
1,713.00
1,453.90
1,890.90
1,148.50
803.60
653.50
652.60
711.00
506.00
PAT before Minority Interest
1,652.50
1,851.80
1,747.60
1,483.00
1,921.30
1,186.10
836.20
689.90
681.20
736.10
529.80
Minority Interest
-64.90
-49.90
-34.60
-29.10
-30.40
-37.60
-32.60
-36.40
-28.60
-25.10
-23.80
PAT Margin
12.47%
13.69%
14.39%
15.51%
20.06%
13.28%
11.12%
10.28%
12.40%
15.35%
13.72%
PAT Growth
-17.85%
5.19%
17.82%
-23.11%
64.64%
42.92%
22.97%
0.14%
-8.21%
40.51%
 
Unadjusted EPS
16.52
18.06
17.35
14.53
19.19
11.24
39.25
31.92
31.87
34.73
24.67

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
10,386.30
8,744.50
6,960.00
5,699.20
4,251.60
3,439.00
2,944.50
2,585.90
2,171.50
1,628.50
Share Capital
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
68.20
Total Reserves
10,283.90
8,642.10
6,857.60
5,596.80
4,149.20
3,336.60
2,842.10
2,483.50
2,069.10
1,560.30
Non-Current Liabilities
3,491.10
2,122.20
1,903.30
736.10
1,341.50
1,589.20
1,640.00
1,555.10
956.30
1,204.60
Secured Loans
1,578.00
200.60
319.60
393.80
664.00
851.40
917.20
901.90
670.90
978.20
Unsecured Loans
2,371.70
2,354.50
2,148.80
502.60
486.40
510.80
508.80
420.40
92.00
112.30
Long Term Provisions
184.10
155.90
151.20
120.70
90.40
76.10
66.50
75.60
61.90
0.00
Current Liabilities
7,342.50
6,083.00
5,305.80
3,461.00
3,285.10
2,814.00
2,670.40
2,191.60
1,415.90
871.10
Trade Payables
1,922.60
1,888.40
1,547.90
1,308.10
1,090.90
910.80
656.80
545.50
570.60
619.60
Other Current Liabilities
2,033.60
1,484.90
1,212.10
860.70
628.20
708.10
509.20
730.90
367.30
56.40
Short Term Borrowings
3,196.90
2,557.50
2,476.90
1,210.90
1,183.50
902.40
1,257.10
687.10
259.80
0.00
Short Term Provisions
189.40
152.20
68.90
81.30
382.50
292.70
247.30
228.10
218.20
195.10
Total Liabilities
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00
4,610.60
3,743.40
Net Block
12,163.70
6,482.60
5,755.10
3,747.90
3,352.20
3,123.80
3,025.60
2,857.10
1,832.60
1,684.40
Gross Block
15,702.30
9,338.50
8,102.90
5,767.30
5,138.50
4,664.00
4,376.20
3,990.90
2,801.70
2,557.80
Accumulated Depreciation
3,538.60
2,842.50
2,345.80
2,016.80
1,786.30
1,540.20
1,350.60
1,096.00
929.90
835.00
Non Current Assets
14,014.70
8,911.00
8,302.90
5,751.70
4,820.40
4,548.60
4,182.50
3,610.00
2,485.30
1,953.30
Capital Work in Progress
837.20
1,527.20
1,543.30
950.80
797.90
891.50
735.60
483.90
431.00
211.10
Non Current Investment
443.60
470.90
385.70
217.10
33.20
22.20
21.20
21.20
20.70
20.70
Long Term Loans & Adv.
410.40
300.00
384.70
661.20
637.10
511.10
400.10
247.80
201.00
0.00
Other Non Current Assets
159.80
130.30
234.10
174.70
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
8,498.10
8,229.70
6,022.30
4,280.40
4,226.70
3,437.90
3,191.70
2,813.00
2,125.30
1,779.90
Current Investments
229.90
274.80
49.10
199.10
121.20
64.40
93.30
3.00
0.00
0.00
Inventories
2,688.00
2,385.30
1,803.70
1,337.10
1,535.70
1,367.50
1,213.60
1,090.50
811.90
750.40
Sundry Debtors
3,950.80
3,206.30
2,277.50
1,746.60
1,588.40
1,133.70
955.10
920.90
765.20
466.80
Cash & Bank
649.30
1,314.90
1,543.50
638.70
669.90
548.80
583.80
466.60
295.20
250.70
Other Current Assets
980.10
318.30
80.00
124.10
311.50
323.50
345.90
332.00
253.00
312.00
Short Term Loans & Adv.
584.50
730.10
268.50
234.80
240.80
254.90
279.00
274.60
206.20
308.00
Net Current Assets
1,155.60
2,146.70
716.50
819.40
941.60
623.90
521.30
621.40
709.40
908.80
Total Assets
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00
4,610.60
3,743.40

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
2,882.30
919.30
1,311.70
1,893.50
993.60
902.80
603.40
511.10
682.60
695.40
PBT
2,382.10
2,312.00
1,611.90
2,098.70
1,445.50
942.20
808.70
794.20
842.50
603.90
Adjustment
664.30
624.30
333.70
249.80
344.50
269.00
315.90
320.90
208.40
228.10
Changes in Working Capital
637.80
-1,383.90
-411.20
271.70
-377.00
-20.10
-201.60
-421.70
-175.30
-123.60
Cash after chg. in Working capital
3,684.20
1,552.40
1,534.40
2,620.20
1,413.00
1,191.10
923.00
693.40
875.60
708.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-675.40
-620.60
-237.60
-646.00
-386.90
-172.80
-272.00
-143.50
-152.50
-77.10
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
-126.50
-12.50
14.90
-80.70
-32.50
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-5,738.70
-973.70
-2,871.90
-863.50
-464.70
-438.00
-682.30
-1,199.50
-466.00
-371.60
Net Fixed Assets
-569.90
-600.20
-557.40
-531.50
-271.50
-239.50
-646.90
-361.70
-266.60
-223.80
Net Investments
-1,106.80
305.60
-1,606.20
-108.40
-651.40
-277.80
-67.70
-513.40
-99.90
-3.50
Others
-4,062.00
-679.10
-708.30
-223.60
458.20
79.30
32.30
-324.40
-99.50
-144.30
Cash from Financing Activity
1,884.60
51.50
2,315.80
-934.80
-351.10
-528.70
285.80
859.80
-172.10
-324.80
Net Cash Inflow / Outflow
-971.80
-2.90
755.60
95.20
177.80
-63.90
206.90
171.40
44.50
-1.00
Opening Cash & Equivalents
1,589.70
1,592.60
837.00
737.90
612.60
676.50
469.60
295.20
250.70
251.70
Closing Cash & Equivalent
879.20
1,589.70
1,592.60
837.00
790.40
612.60
676.50
466.60
295.20
250.70

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
101.43
85.40
67.97
55.66
41.52
33.58
28.75
25.25
21.21
15.82
ROA
9.34%
11.11%
12.18%
20.14%
13.93%
10.89%
10.00%
12.35%
17.62%
14.94%
ROE
19.36%
22.26%
23.43%
38.62%
30.85%
26.20%
24.95%
28.64%
38.85%
37.71%
ROCE
15.88%
18.41%
16.50%
28.60%
23.21%
17.20%
18.21%
24.01%
30.56%
26.55%
Fixed Asset Turnover
1.05
1.37
1.38
1.76
1.80
1.63
1.55
1.58
1.75
1.54
Receivable days
99.21
83.84
76.72
63.29
56.38
51.71
52.78
57.47
47.97
45.13
Inventory Days
70.33
64.05
59.88
54.52
60.13
63.89
64.82
64.85
60.83
66.19
Payable days
72.33
71.22
74.18
67.53
55.78
50.51
43.54
49.87
64.40
75.83
Cash Conversion Cycle
97.21
76.67
62.42
50.28
60.73
65.09
74.05
72.45
44.40
35.49
Total Debt/Equity
0.76
0.62
0.75
0.43
0.62
0.79
0.99
0.89
0.50
0.67
Interest Cover
13.31
21.87
26.55
40.75
22.29
11.45
5.79
5.35
13.05
8.36

News Update


  • Zydus receives marketing authorization for RabiMabs from Drug Controller General of India
    3rd Sep 2019, 09:41 AM

    Twinrab, is indicated in combination with rabies vaccine for rabies post-exposure prophylaxis

    Read More
  • Zydus Cadila gets USFDA’s nod for Ranolazine Extended-Release Tablets
    21st Aug 2019, 14:00 PM

    It will be manufactured at the group’s formulations manufacturing facility at Baddi

    Read More
  • Zydus Cadila initiates Phase 2 clinical trial of Saroglitazar Magnesium in NAFLD with PCOS
    21st Aug 2019, 11:49 AM

    The EVIDENCES VII trial is currently recruiting patients across several clinical sites in the United States of America and Mexico

    Read More
  • Cadila Healthcare reports 34% fall in Q1 consolidated net profit
    9th Aug 2019, 15:57 PM

    Total consolidated income of the company increased by 17.49% at Rs 3,518.90 crore for Q1FY20

    Read More
  • Cadila Healthcare - Quarterly Results
    9th Aug 2019, 15:11 PM

    Read More
  • USFDA classifies inspection of Cadila Healthcare’s Moraiya unit as OAI
    7th Aug 2019, 11:32 AM

    The company believes that this classification will not have any impact on the current supplies or revenues of this facility

    Read More
  • Zydus Cadila completes Phase 3 Trial of Saroglitazar Magnesium
    2nd Aug 2019, 11:20 AM

    The Phase 3 trial enrolled 1140 subjects and studied the patients over a period of 56 weeks

    Read More
  • USFDA concludes inspection at Zydus Cadila’s API manufacturing facilities in Ankleshwar
    27th Jul 2019, 09:47 AM

    At the end of the inspection, no observation is issued

    Read More
  • Zydus Cadila launches Ramelteon Tablets
    24th Jul 2019, 10:26 AM

    The drug will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad

    Read More
  • Zydus Cadila’s arm gets USFDA’s nod for Dextroamphetamine Saccharate
    19th Jul 2019, 14:46 PM

    The company has also received approval for Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate, and Amphetamine Sulfate

    Read More
  • Zydus Cadila completes enrollment in Evidences III of Saroglitazar Magnesium
    18th Jul 2019, 11:47 AM

    Patients with NASH have been enrolled in these trials across clinical sites in India and Mexico

    Read More
  • Zydus Cadila gets USFDA’s nod for Misoprostol Tablets
    3rd Jul 2019, 14:12 PM

    The drug will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad

    Read More
  • Zydus Cadila completes enrolment in Evidences IV phase 2 clinical trial of Saroglitazar Magnesium
    17th Jun 2019, 14:49 PM

    The trial will evaluate the percentage change from baseline in serum ALT levels in patients treated with Saroglitazar Magnesium as compared to placebo as the primary endpoint

    Read More
  • Cadila Healthcare receives EIR for its formulations manufacturing facility
    17th Jun 2019, 14:13 PM

    The EIR report has stated that the classification of the facility is 'Voluntary Action Indicated'

    Read More
  • Zydus’ Nesher Pharmaceuticals gets final nod for Omega-3-Acid Ethyl Esters Capsules
    17th Jun 2019, 11:42 AM

    Omega-3 acid ethyl esters, a type of fat found in fish oil, is used along with diet and exercise to help lower levels of a certain blood fat (triglyceride)

    Read More
  • Cadila Healthcare’s arm receives EIR for manufacturing facility in Ahmedabad
    15th Jun 2019, 11:28 AM

    The USFDA had conducted a PAI for Doxorubicin Liposomal, a complex oncological injectable at Alidac, the injectable onco manufacturing facility, from March 18 to March 26, 2019

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.